Real-World Insights on Cell and Gene Therapy Development: Navigating the Complexities of Critical Quality Attributes
Fill out the form below and we'll send your colleague an invitation to the "Real-World Insights on Cell and Gene Therapy Development: Navigating the Complexities of Critical Quality Attributes" event.
Cell and gene therapies (CGTs) are progressing so rapidly, the question is; can critical quality attribute (CQA) assays keep up? Whether your in vivo therapy is being delivered by adeno-associated viruses or other viruses, lipid nanoparticles or virus-like particles, or it’s an autologous or allogeneic ex vivo gene therapy, all CGTs need to demonstrate identity, safety, purity, potency and stability.
In this panel discussion, you’ll gain insights from experts in CGT development who will explore their experiences of CQA assays, sharing advice on how to overcome the challenges you may face in your CGT journey.
- Learn what the critical quality attributes are for cell and gene therapy development
- Explore the importance of analyzing CQAs to ensure cell and gene therapy safety and potency
- Discover success criteria for better preclinical and critical outcomes